Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response – results of a phase II regimen‐finding trial

The social stigma and chronicity of psoriasis significantly affect health‐related quality of life (HRQoL).

[1]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[2]  T. Nijsten,et al.  Measurement of health‐related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  J. Ortonne,et al.  Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study , 2012, The British journal of dermatology.

[4]  U. Persson,et al.  Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice , 2013, Dermatology.

[5]  L. Naldi,et al.  The Burden of Moderate to Severe Psoriasis , 2012, PharmacoEconomics.

[6]  C. Griffiths,et al.  Biologics for psoriasis: current evidence and future use , 2012, The British journal of dermatology.

[7]  L. Naldi,et al.  A framework for improving the quality of care for people with psoriasis , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  U. Persson,et al.  Analysis of three outcome measures in moderate to severe psoriasis: a registry‐based study of 2450 patients , 2012, The British journal of dermatology.

[9]  T. Nijsten,et al.  A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO). , 2012, European journal of dermatology : EJD.

[10]  E. Berardesca,et al.  Health-related quality of life in psoriasis: an analysis of Psocare project patients. , 2011, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[11]  A. Parodi,et al.  The quality of life in Italian psoriatic patients treated with biological drugs. , 2010, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[12]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[13]  A. Finlay,et al.  The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.

[14]  S. Feldman,et al.  Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study , 2008, Health and quality of life outcomes.

[15]  Elizabeth J Horn,et al.  National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. , 2008, Journal of the American Academy of Dermatology.

[16]  K. Reich,et al.  Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany , 2008, Dermatology.

[17]  J. Schmitt,et al.  Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population‐based study , 2007, The British journal of dermatology.

[18]  C. Griffiths,et al.  Pathogenesis and clinical features of psoriasis , 2007, The Lancet.

[19]  R. Shikiar,et al.  Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trial , 2007, The Journal of dermatological treatment.

[20]  R. Shikiar,et al.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study , 2006, Health and quality of life outcomes.

[21]  F. Nestle,et al.  Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate‐to‐severe psoriasis: a randomized controlled trial , 2006, The British journal of dermatology.

[22]  A. Finlay,et al.  Translating the science of quality of life into practice: What do dermatology life quality index scores mean? , 2005, The Journal of investigative dermatology.

[23]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS INDICATED FOR THE TREATMENT OF PSORIASIS , 2004 .

[24]  W. Stolz,et al.  Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? , 2003, The British journal of dermatology.

[25]  M. Lebwohl,et al.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. , 2001, Archives of dermatology.

[26]  E M Farber,et al.  The prevalence of psoriasis in the world , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  D M Reboussin,et al.  Psoriasis causes as much disability as other major medical diseases. , 1999, Journal of the American Academy of Dermatology.

[28]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[29]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.